FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENTCollaboration, License and Option Agreement • November 3rd, 2016 • Curis Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENT (the “Amendment”) is entered into as of September 7, 2016 (the “Amendment Date”), by and between AURIGENE DISCOVERY TECHNOLOGIES LIMITED, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and CURIS, INC., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (“Curis”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 3rd, 2016 • Curis Inc • Biological products, (no disgnostic substances) • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 7, 2016, is entered into between Curis, Inc., a Delaware corporation (the “Company”), and Aurigene Discovery Technologies Limited, a company organized under the laws of India (the “Purchaser”).
CURIS, INC.Recognition Bonus Agreement • November 3rd, 2016 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Curis, Inc. (the “Company”) appreciates your many years of service in varying roles including as Chief Executive Officer, President, Vice-Chairman of the Board of Directors (the “Board”) and as a consultant. In recognition of such service, this letter agreement will memorialize certain arrangements between the Company and you, as well as resolve any outstanding issues there may be. This Agreement may be accepted by you by providing an executed agreement which is received by the Company by no later than August 31, 2016, after which time the Agreement and the offer embodied within it, shall be effectively withdrawn.
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • November 3rd, 2016 • Curis Inc • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of September 7, 2016 (the “Effective Date”) is between Curis, Inc., a Delaware corporation (the “Company”), and Aurigene Discovery Technologies Limited, a company organized under the laws of India (the “Purchaser”). Capitalized terms set forth herein and not defined shall have the meanings ascribed to such terms under the License Agreement (as defined below).
